These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 8853931

  • 1. Clinical pharmacokinetics of topotecan.
    Herben VM, ten Bokkel Huinink WW, Beijnen JH.
    Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
    Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC.
    Drug Metab Dispos; 1992 Aug; 20(5):706-13. PubMed ID: 1358575
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical pharmacokinetics of irinotecan.
    Chabot GG.
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [Abstract] [Full Text] [Related]

  • 8. Clinical, pharmacokinetic and biological studies of topotecan.
    O'Dwyer PJ, LaCreta FP, Haas NB, Halbherr T, Frucht H, Goosenberg E, Yao KS.
    Cancer Chemother Pharmacol; 1994 Oct; 34 Suppl():S46-52. PubMed ID: 8070027
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
    van Warmerdam LJ, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JH, ten Bokkel Huinink WW, Davies BE, Maes RA, Verweij J, Beijnen JH.
    Cancer Chemother Pharmacol; 1996 Oct; 38(3):254-60. PubMed ID: 8646800
    [Abstract] [Full Text] [Related]

  • 10. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
    Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG.
    Cancer Res; 1993 Feb 15; 53(4):725-7. PubMed ID: 8428353
    [Abstract] [Full Text] [Related]

  • 11. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1994 Mar 01; 54(5):1220-6. PubMed ID: 8118810
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D.
    Clin Cancer Res; 1995 Mar 01; 1(3):269-76. PubMed ID: 9815982
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Reduced albumin binding promotes the stability and activity of topotecan in human blood.
    Mi Z, Malak H, Burke TG.
    Biochemistry; 1995 Oct 24; 34(42):13722-8. PubMed ID: 7577964
    [Abstract] [Full Text] [Related]

  • 19. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
    Dowlati A, Levitan N, Gordon NH, Hoppel CL, Gosky DM, Remick SC, Ingalls ST, Berger SJ, Berger NA.
    Cancer Chemother Pharmacol; 2001 Oct 24; 47(2):141-8. PubMed ID: 11269740
    [Abstract] [Full Text] [Related]

  • 20. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.
    Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL.
    Cancer Res; 1994 Oct 01; 54(19):5118-22. PubMed ID: 7923128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.